Background-Reinfarction after primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction has negative consequences. Little is known about reinfarction after drug-eluting stents and bivalirudin anticoagulation. We, therefore, sought to determine the incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in the contemporary era. Methods and Results-Outcomes were assessed in 3202 patients undergoing stent implantation for ST-segment-elevation myocardial infarction in the Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Independent predictors of reinfarction and mortality were identified by Cox proportional hazards modeling. The cumulative incidence of reinfarction was 1.8% at 30 days, 4.0% at 1 year, and 6.9% at 3 years. Definite stent thrombosis was responsible for 76.3% of reinfarctions occurring within 30 days and 52.0% of all reinfarctions within 3 years. Independent predictors of reinfarction were current smoking, Killip class ≥2, baseline thrombocytosis, multivessel disease, symptom onset-to-balloon time, and total stent length. Randomization to bivalirudin versus heparin plus a glycoprotein IIb/ IIIa inhibitor and use of drug-eluting versus bare metal stents were not significant predictors of reinfarction. Reinfarction was a powerful independent predictor of subsequent cardiac mortality (hazard ratio [95% confidence interval]=7. 65 [4.47-13.09]; P<0.0001) and all-cause mortality (hazard ratio [95% confidence interval]=2.88 [1.74-4.78]; P<0.0001).
R einfarction in patients with ST-segment-elevation myocardial infarction (STEMI) is defined by recurrent clinical signs and symptoms of ischemia distinct from the index event, with concomitant electrocardiographic changes and serum biomarker evidence of myocardial necrosis. 1 Reinfarction has consistently been identified as an independent predictor of mortality in observational studies and randomized trials spanning the prereperfusion, 2-5 fibrinolysis, 6, 7 and primary angioplasty [8] [9] [10] eras. Most prior primary percutaneous coronary intervention (PCI) trials examining the frequency, causes, and implications of reinfarction were performed in patients anticoagulated with unfractionated heparin (UFH) with or without glycoprotein IIb/IIIa inhibitors (GPI) and treated with balloon angioplasty or bare metal stents. Management of STEMI has since evolved, with frequent use of bivalirudin anticoagulation (without routine GPI) and drug-eluting stents (DES). The incidence, predictors, and consequences of reinfarction with contemporary treatment of STEMI have not been reported. We therefore performed a comprehensive analysis of reinfarction from the Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.
Methods

Study Design and Participants
Details of the HORIZONS-AMI protocol have been previously reported. 11 In brief, HORIZONS-AMI was a prospective, open-label, 2×2 factorial randomized multicenter trial that enrolled 3602 patients presenting with STEMI within 12 hours of symptom onset. All patients were randomized in a 1:1 ratio to anticoagulation with UFH+GPI versus bivalirudin monotherapy (with provisional GPI use allowed only for refractory ischemic or thrombotic complications). Stents were implanted in a total of 3202 patients, including 3006 patients who were randomized in a 3:1 ratio to Taxus paclitaxel-eluting DES or otherwise identical bare metal stents, and 196 additional patients with lesions excluded from randomization. 11 Clinical follow-up was performed at 30 days, 6 months, 1 year, 2 years, and 3 years after the index PCI. The study was approved by the institutional review board or ethics committee at each participating center, and all enrolled patients provided informed written consent.
End Points and Definitions
The present analysis included all participants who underwent primary PCI with stent implantation (n=3202). The baseline characteristics, angiographic and procedural features, and clinical outcomes in patients with versus without reinfarction were examined. The detailed definition of reinfarction (with subclassification as Q wave versus non-Q wave) as adjudicated in the HORIZONS-AMI trial has been reported previously 11 and appears in the Appendix in the Data Supplement. The primary outcome end points of interest in patients with versus without reinfarction were cardiac mortality and all-cause mortality at 3-year follow-up, with secondary end points including ischemia-driven target vessel revascularization, stroke, and major bleeding unrelated to coronary artery bypass graft surgery, each as previously defined. 11 Stent thrombosis was adjudicated according to the Academic Research Consortium criteria. 12 An independent clinical events committee blinded to treatment allocation adjudicated all end point events using original source documentation.
Statistical Analysis
Categorical variables are presented as percentages except where noted and were compared with the χ 2 test or Fisher exact test as appropriate. Continuous variables are presented as medians with interquartile range and were compared with the Wilcoxon rank sum test. Timeto-event curves were constructed using Kaplan-Meier methodology, and event rate estimates during follow-up were compared with the log-rank test. Cox proportional hazards regression was performed to determine the independent predictors of reinfarction, cardiac mortality, and all-cause mortality at 3-year follow-up. Candidate variables for inclusion were chosen based on previously identified risk factors for reinfarction and death, with the total number of variables limited to avoid model overfitting according to the number of events (10:1 ratio). Variables entered into the reinfarction model included age, sex, diabetes mellitus, current smoking, hypertension, hyperlipidemia, Killip classification, body mass index, time to reperfusion, PCI infarct artery, baseline creatinine clearance, baseline hemoglobin, baseline leukocyte count, baseline platelet count, multivessel disease, multiple lesions treated, randomization to bivalirudin (versus UFH+GPI), DES use (versus only bare metal stents use), total stent length, stent diameter, and baseline and final Thrombolysis in Myocardial Infarction flow. Candidate variables for the mortality models included age, sex, diabetes mellitus, Killip classification, infarct artery, baseline hemoglobin, baseline creatinine clearance, baseline Thrombolysis in Myocardial Infarction flow, randomization to bivalirudin, and DES use. In addition, major bleeding and reinfarction were entered into each mortality model as time-dependent variables in which the bleeding or reinfarction variable was 0 before the event and 1 after. All statistical tests were 2-tailed. P<0.05 were considered statistically significant. All analyses were performed using SAS 9.2 (SAS Institute, Cary, NC).
Results
Median (interquartile range) follow-up time was 3.00 (2.97-3.03) years. A total of 264 reinfarctions had occurred in 221 patients (6.9%) by 3 years; 29 patients (0.8%) had multiple reinfarctions. Q waves were present in 125 of 264 reinfarctions (47.3%). The median (interquartile range) time to first reinfarction was 244 (22-573) days. As shown in Figure 1 , the greatest risk of first reinfarction was within 30 days after PCI (≈1.8% of patients), with a steady increase thereafter through 3 years.
WHAT IS KNOWN
• Reinfarction is a major cause of morbidity and mortality after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction.
WHAT THE STUDY ADDS
• In the contemporary primary percutaneous coronary intervention era, reinfarction still occurs in ≈1 in 14 patients within 3 years, with a steady and ongoing risk.
• The most common cause of reinfarction after primary percutaneous coronary intervention is stent thrombosis, with the first 30 days being the greatest risk period.
• Reinfarction confers a ≈8-fold increased 3-year risk of cardiac mortality.
• Several baseline and procedural factors may be modified to reduce the rate of reinfarction. Reinfarction occurred in 1.8% of patients at 30 days, 4.0% at 1 year, 5.7% at 2 years, and 6.9% at 3 years. The incidence of reinfarction was highest in the first 30 days, with an ongoing risk of reinfarction thereafter.
Predictors of Reinfarction
The occurrence of reinfarction during the 3-year follow-up period was associated with smoking, insulin-treated diabetes mellitus, prior myocardial infarction, prior PCI, prior coronary artery bypass graft surgery, peripheral artery disease, dialysis treatment, enrollment in the United States, and baseline aspirin, thienopyridine, β-blocker, and angiotensinconverting enzyme inhibitor or angiotensin receptor blocker medication use (Table 1) . Patients with reinfarction were more likely to have undergone multivessel PCI, with longer procedures using more fluoroscopy and contrast ( Table 2 ). Femoral access use was slightly more common in patients with reinfarction. Use of bivalirudin as compared with UFH+GPI was associated with less reinfarction, whereas there was no relationship between stent type and risk of reinfarction. A lower postprocedural nadir hemoglobin was also associated with reinfarction. Regarding medications, use of a 300 mg clopidogrel loading dose (rather than 600 mg) was more common among patients with reinfarction, and discharge prescription of thienopyridines and statins (and thienopyridine use at 30 days) was less common among those who developed reinfarction during follow-up (Table 3) . Conversely, dual antiplatelet agent use during follow-up at 2 and 3 years was more common in patients in whom reinfarction developed. By multivariable analysis, the independent baseline predictors of reinfarction at 3-year follow-up were current smoking, acute heart failure (Killip classification ≥2), elevated baseline platelet count, multivessel disease, longer symptom onset-to-balloon time, and greater total implanted stent length ( Table 4 ). Use of bivalirudin rather than UFH+GPI was a borderline predictor of less reinfarction in this model but did not reach statistical significance (hazard ratio [95% confidence interval]=0.77 [0.59-1.02]; P=0.07).
Relationship Between Stent Thrombosis and Reinfarction
Angiographically confirmed definite stent thrombosis within 3 years developed in 136 patients (Kaplan-Meier estimated rate=4.4%), 127 (93.4%) of which originated within target lesion stents implanted during the index STEMI procedure. Reinfarction developed in 115 of 136 patients (84.6%) with definite stent thrombosis, including 106 of 127 patients (83.5%) with target lesion stent thrombosis and 9 of 9 patients (100%) with nontarget lesion stent thrombosis. Among the 127 patients in whom definite target lesion stent thrombosis developed, a myocardial infarction was less likely to result when the stent thrombosis episode developed within the first 30 days after the index PCI (early stent thrombosis) compared with beyond 30 days of stent implantation (late or very late stent thrombosis; 43/61 [70.5%] versus 63/66 [95.5%], respectively; P=0.0002; Figure 2 ). Definite stent thrombosis was responsible for 115 of the 221 cases of reinfarction (52.0%), including 45 of the 59 patients (76.3%) developing reinfarction within 30 days and 70 of the 162 patients (43.2%) developing reinfarction between 30 days and 3 years ( Figure 3 ). Probable stent thrombosis was also adjudicated in an additional 6 patients (3.0%) with reinfarction, occurring before 30 days, between 30 days and 1 year, and between 1 year and 3 years in 1, 1, and 4 patients, respectively.
Relationship Between Reinfarction and Adverse Events
As shown in Table 5 , the occurrence of reinfarction was strongly associated with the 3-year rates of cardiac and allcause mortality, stroke, ischemia-driven target vessel revascularization, and noncoronary artery bypass graft surgery-related major bleeding. As a time-dependent variable, reinfarction was an independent predictor of subsequent 3-year cardiac mortality and all-cause mortality (hazard ratio [95% confidence interval]=7.65 [4.47-13 .09]; P<0.0001 and 2.88 [1.74-4.78]; P<0.0001, respectively; Table 6 ). In patients with reinfarction either due (n=115) or not due (n=106) to definite stent thrombosis, the 3-year Kaplan-Meier rates of cardiac mortality were 7.1% (n=8) versus 12.6% (n=13), respectively (P=0.18), and the 3-year rate of all-cause mortality was 11.7% (n=13) versus 14.5% (n=15), respectively (P=0.50).
Discussion
In the large-scale, multinational HORIZONS-AMI trial, reinfarction after stent implantation occurred in 1.8% of patients at 30 days and in 6.9% of patients at 3 years, with no interval observed where the ongoing risk was negligible. Definite stent thrombosis was responsible for more than half of all reinfarctions. Neither the randomized pharmacological regimen nor stent type impacted the risk of reinfarction. Reinfarction was a powerful independent predictor of cardiac and all-cause mortality during long-term follow-up.
During the past 3 decades, the rate of reinfarction has declined as treatment transitioned from the prereperfusion and fibrinolysis eras to the current primary PCI era. In 1984, the Multicenter Postinfarction Research Group reported a 1-year reinfarction rate of 12.9% in 866 patients surviving the initial phase of STEMI. 2 In 1992, the Thrombolysis in Myocardial Timing of target lesion definite stent thrombosis Figure 2 . Likelihood of a target lesion stent thrombosis event causing reinfarction according to its timing after the index procedure.
Infarction investigators reported a 1-year reinfarction rate of 9.6% in 3339 patients treated with intravenous recombinant tissue-type plasminogen activator with or without invasive angiography and revascularization. 13 In 23 trials in which 7739 patients were randomized, reinfarction at 6 to 18 months occurred in 6.8% of patients treated with fibrinolysis versus 2.5% with balloon angioplasty (P<0.0001). 14 Although direct comparisons of reinfarction rates between the present and earlier studies are limited by heterogeneity in definitions and varying follow-up durations and completeness, the 4.0% 1-year rate of reinfarction in HORIZONS-AMI demonstrates with certainty that reinfarction after primary PCI has not been eliminated, despite evolution in pharmacotherapy, device technology, and implantation technique during the past 3 decades. In this regard, despite markedly decreasing major bleeding, cardiac death, and all-cause mortality at 3 years, 15 treatment with bivalirudin rather than UFH+GPI did not significantly reduce reinfarction after multivariable adjustment. Nor was paclitaxeleluting stent use effective in preventing reinfarction, despite its marked effects in reducing angiographic restenosis and ischemia-driven target vessel revascularization. 15, 16 These findings support the results of other randomized trials demonstrating that reinfarction rates after primary PCI have not been further reduced by either bare metal stents 17 or first generation DES. 18 Consistent with prior reports, 8-10 the highest risk period for reinfarction in HORIZONS-AMI was the first 30 days after primary PCI. Of note, more than half of reinfarctions were associated with new Q waves, likely because of the difficulty in detecting small reinfarctions in patients after STEMI. As such, the present (and prior) studies may have underestimated the true incidence of reinfarction. A novel finding of the present study is the extent to which the reinfarction risk was attributable to stent thrombosis: 76.3% of reinfarctions occurring within 30 days and 52.0% of all reinfarctions within 3 years were caused by definite stent thrombosis. These findings emphasize the potential to decrease reinfarction rates substantially if reductions in stent thrombosis can be achieved with further improvements in stent technology and pharmacotherapy. Newer generation metallic DES with novel thromboresistant polymers or metals or bioabsorbable polymers may be particularly effective in this regard. [19] [20] [21] [22] Moreover, ADP antagonists more potent than clopidogrel, including prasugrel, ticagrelor, and cangrelor, may reduce stent thrombosis and reinfarction rates, especially in the early risk period. [23] [24] [25] Of note, whereas the proportion of reinfarctions attributable to angiographically confirmed stent thrombosis was greatest in the early postmyocardial infarction period, the likelihood of stent thrombosis resulting in reinfarction (compared with an acute coronary syndrome without myonecrosis) increased progressively during follow-up. Although the reasons for this are uncertain, contributing factors may include less extensive thrombosis and more rapid treatment in the acute and subacute phases (especially before coronary care unit and hospital discharge), collateral regression over time, and difficulties with diagnosing reinfarction in the early peri-infarction period (when ECG and biomarkers are still abnormal).
The predictors of reinfarction identified in the present study suggest additional possible pathways to prevent this complication after primary PCI. Presentation with acute heart failure (Killip class ≥2), reflecting greater myocardium at risk (infarcted and stunned) with reduced systolic left ventricular function, was an important independent predictor of subsequent reinfarction, consistent with prior studies. [8] [9] [10] Therapies to enhance myocardial salvage, such as intravenous β-blockade, intralesional abciximab, systemic hypothermia, and supersaturated oxygen, may therefore be useful to prevent reinfarction. [26] [27] [28] [29] Multivessel disease was also an independent predictor of reinfarction in the present study. A recently reported 465 patient randomized trial suggests that both reinfarction and survival may be reduced by a strategy of complete multivessel revascularization at the time of primary PCI, 30 possibly through treatment of nonculprit vulnerable plaques which are known to be frequent in patients with STEMI. 31 Larger studies are required to confirm this approach. Another risk factor for reinfarction was cigarette smoking, and smoking cessation may reduce reinfarction after STEMI. 32, 33 Reinfarction was also more common in patients with baseline thrombocytosis. An association between platelet count and cardiovascular mortality after STEMI has been described. 34 Although baseline thrombocytosis may reflect an acute phase response in the setting of a more extensive infarct, it is possible that quantitative or qualitative differences in platelet count and activity may predispose to stent thrombosis and reinfarction. The relationships between reinfarction and both time to reperfusion and stent length (by increasing stent thrombosis risk) provide further motivation to rapid reperfusion and restricting stent coverage to necessary segments of the infarct lesion. Finally, less discharge prescription and 30-day thienopyridine use was also associated with reinfarction, confirming this previously described relationship. 35 Conversely, dual antiplatelet agent use was more common in patients with reinfarction at 2-year and 3-year follow-up, likely a consequence rather than a cause of this event. Strict emphasis on dual antiplatelet agent adherence for ≥1 year after stent implantation in STEMI may reduce reinfarction. 23, 24, 35 In the present study, reinfarction was strongly related to subsequent cardiac and all-cause mortality. Reinfarction occurring within 3 years was also associated with other adverse outcomes, including ischemia-driven target vessel revascularization, stroke, and noncoronary artery bypass graft surgery major bleeding. Major bleeding, in particular, has also been linked with subsequent mortality. 36, 37 However, after multivariable adjustment for baseline covariates including major bleeding, reinfarction remained a powerful independent predictor of both 3-year cardiac and all-cause mortality. These data thus suggest that prevention of both reinfarction and major bleeding complications after primary PCI in STEMI may further improve survival.
This study has several limitations. The present post hoc analysis is subject to residual confounding of the multivariable models. Episodes of silent reinfarction may not have been detected. Detailed data were not available concerning the exact timing of medication discontinuation, and as such the well-described relationship between disruption of antiplatelet therapies and stent thrombosis and reinfarction 38 could not be assessed. The present study was also not designed to determine the causes of the 106 reinfarctions unrelated to definite stent thrombosis, whether because of unconfirmed thrombotic events, incomplete revascularization, disease progression, or other mechanisms. Finally, HORIZONS-AMI did not use second-or later-generation stents and potent ADP antagonists, which may reduce the frequency of stent thrombosis and reinfarction [19] [20] [21] [22] [23] [24] [25] but are unlikely to affect the effect of reinfarction on subsequent mortality.
In conclusion, in patients undergoing primary PCI with stent implantation for STEMI in the HORIZONS-AMI trial, reinfarction was not infrequent, occurring in ≈1 of every 14 patients within 3 years, with an ongoing risk evident over time. Stent thrombosis was the most frequent cause of reinfarction, with the first 30 days being the greatest risk period for both stent thrombosis and reinfarction. Several modifiable baseline and procedural factors were identified as independent predictors of reinfarction. As the occurrence of reinfarction conferred a ≈8-fold and ≈3-fold increase in the subsequent risk of cardiac and all-cause mortality, major investigative efforts are warranted to further reduce the occurrence of reinfarction after primary PCI in STEMI.
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